Rong Tang - Concepedia

Author

Rong Tang

Jiangsu Provincial Center for Disease Control and Prevention ORCID

Also Known As

Rong Tang, Tang Rong, Weiyun Mu

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Jiangsu Provincial Center for Disease Control and Prevention Nanjing Medical University Academy of Military Medical Sciences CanSino (China)Southeast University

About

Rong Tang is an author at Jiangsu Provincial Center for Disease Control and Prevention specializing in medicine, vaccine safety, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	459
2	Immunology	5	5	333
3	Public Health	1	1	95
4	Epidemiology	1	1	95
5	Obstetrics	1	1	126

Rong Tang

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Yanjun Zhang, Gang Zeng, Hongxing Pan, The Lancet Infectious Diseases	2020	1.5K
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial Jingxin Li, Shipo Wu, Xiling Guo, The Lancet Respiratory Medicine VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetImmunology	2022	164
Associations of prenatal exposure to phenols with birth outcomes Rong Tang, Minjian Chen, Guodong Ding, Environmental Pollution Early Life ExposureGynecologyMaternal HealthPreterm BirthPlacental Disease	2013	126
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial Jingxin Li, Lihua Hou, Fanyue Meng, The Lancet Global Health	2016	101
Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical Trial Yanjun Zhang, Gang Zeng, Hongxing Pan, Placebo-controlled Phase 2ImmunologyVaccine HesitancyCovid-19Influenza Vaccines	2020	95
Single-cell analysis of angiotensin-converting enzyme II expression in human kidneys and bladders reveals a potential route of 2019 novel coronavirus infection Wei Lin, Jue Fan, Longfei Hu, Chinese Medical Journal	2021	52
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco Yaowen Zhang, Jihane Belayachi, Yunkai Yang, BMC Public Health	2022	50
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial Jingxin Li, Lihua Hou, Jin-Bo Gou, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentOpen-label Phase 3Heterologous Boost	2023	47
Effect of pregravid obesity on perinatal outcomes in singleton pregnancies following in vitro fertilization and the weight-loss goals to reduce the risks of poor pregnancy outcomes: A retrospective cohort study Lu Liu, Hongmei Wang, Yang Zhang, PLoS ONE	2020	39
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial Lairun Jin, Rong Tang, Shipo Wu, Emerging Microbes & Infections	2022	29

Page 1